Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2024 : 1 | 30 | 60

Semaglutide in secondary cardiovascular prevention in overweight or obese patients

 Marketing Authorisations   In a placebo-controlled trial in patients at high risk for cardiovascular events, their incidence was 1.5 percentage points lower in the injectable semaglutide group than in the placebo group, with no reduction in mortality and at a cost of frequent, and often troublesome, adverse effects.
Full article available for download by subscribers

©Prescrire 1 June 2024

Source: "Semaglutide in secondary cardiovascular prevention in overweight or obese patients" Prescrire Int 2024; 33 (260): 157-158. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
See also:

"Semaglutide (Wegovy°)
for excess body weight.
No proven efficacy against
clinical complications
as of late 2022"
Prescrire Int 2023;
32 (245): 36-38.
Subscribers only

"GLP-1 agonists: depression,
suicidal thoughts or behaviour?"
Prescrire Int 2024;